<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Malignant peritoneal mesothelioma: Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Malignant peritoneal mesothelioma: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Malignant peritoneal mesothelioma: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">H Richard Alexander, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hedy Lee Kindler, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna K Nowak, MBBS PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H135335340"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that arises from the lining mesothelial cells of the peritoneum and spreads extensively within the confines of the abdominal cavity. Morbidity and mortality are almost entirely due to disease progression within the peritoneum and not distant metastatic spread.</p><p>This topic review will cover the treatment of MPM. The epidemiology, histology, clinical features, diagnosis, and staging of MPM, as well as the treatment of pleural, pericardial, and tunica vaginalis mesothelioma are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging"</a> and  <a class="medical medical_review" href="/d/html/4625.html" rel="external">"Epidemiology of malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/d/html/4627.html" rel="external">"Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/d/html/4626.html" rel="external">"Initial management of malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H3693022141"><span class="h1">DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA</span></p><p class="headingAnchor" id="H2158870121"><span class="h2">General treatment principles and historic evolution</span><span class="headingEndMark"> — </span>There is no consensus as to the optimal treatment for MPM. Due to the rarity of this entity, most of the available clinical information about treatment has been derived from retrospective single-center series, which have inherent selection biases. Prospective clinical trials are few and small, and there are currently no randomized studies that compare one treatment with another. Much of the data on systemic therapy in MPM are derived from pharmaceutical company Expanded Access Programs, which have more heterogeneous patient populations and less rigorous response assessment and toxicity reporting than a prospective clinical trial. Determinations about the activity of systemic anticancer agents are often extrapolated from the more extensive data available from patients with pleural mesothelioma. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma"</a>.)</p><p>Compounding the difficulty of interpreting data from select small series, MPM is quite heterogeneous in clinical behavior (particularly between men and women) [<a href="#rid1">1,2</a>]. There are many prognostic variables, some of which are only assessable at surgical evaluation. The different histologic types have different natural histories; the sarcomatoid or biphasic subtype has a worse prognosis than the more common epithelial subtype [<a href="#rid3">3,4</a>], and there are two variants, both of which arise predominantly in women, that are associated with indolent clinical behavior. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Histology'</a> and <a class="local">'Peritoneal mesothelioma variants'</a> below.)</p><p>The following sections will focus on diffuse MPM, the most common clinical presentation. Management of the well-differentiated papillary and multicystic variants is described below. (See <a class="local">'Peritoneal mesothelioma variants'</a> below.)</p><p class="headingAnchor" id="H3019487766"><span class="h3">Conventional therapy</span><span class="headingEndMark"> — </span>Diffuse MPM was originally treated with a combination of systemic chemotherapy, palliative surgery, and whole abdominal irradiation [<a href="#rid5">5</a>]. The regimen was exceedingly toxic; median survival was less than one year, and long-term survival was uncommon [<a href="#rid5">5-7</a>]. The median survival for untreated patients is approximately six months [<a href="#rid2">2</a>]. An overview of selected historical series of MPM treated with conventional therapies is provided in the table  (<a class="graphic graphic_table graphicRef130811" href="/d/graphic/130811.html" rel="external">table 1</a>).</p><p>Most of these series are old, and surgical techniques and supportive care have evolved. A Turkish series of 35 patients with MPM provides contemporary insight into the natural history of the disease, as most patients received palliative chemotherapy or supportive care only [<a href="#rid8">8</a>]. The mean age was 59 years and the overall survival time from diagnosis was 16 months. In multivariate analysis, patients who were over age 60, individuals who were exposed to asbestos for &gt;20 years, and those who had an Eastern Cooperative Oncology Group performance status of 3  (<a class="graphic graphic_table graphicRef57945" href="/d/graphic/57945.html" rel="external">table 2</a>) at diagnosis were more likely to have a  poor prognosis. Performance status at diagnosis was the strongest predictor of poor outcome.</p><p>Additional information is available from two retrospective reports comparing outcomes of patients treated with conventional therapies versus cytoreductive surgery (CRS)/hyperthermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) [<a href="#rid9">9,10</a>], described in the following section.</p><p class="headingAnchor" id="H575023267"><span class="h3">Evolution of modern therapy</span><span class="headingEndMark"> — </span>The concept of aggressive surgical cytoreduction and intraperitoneal chemotherapy with hyperthermia for diffuse MPM was introduced in the mid 1990s [<a href="#rid11">11</a>]. Intraperitoneal chemotherapy used in the operating room with hyperthermia has many nomenclatures, including continuous hyperthermic peritoneal perfusion, heated intraoperative peritoneal chemotherapy, and HIPEC. The remainder of this topic review will use the term HIPEC. Some centers also extend the period of IP chemotherapy beyond the operating room, an approach termed early postoperative intraperitoneal chemotherapy (EPIC).</p><p>As experience with CRS and HIPEC has accumulated from several centers, particularly over the last 15 years, marked improvements in outcome have been reported compared with historical controls [<a href="#rid12">12</a>]. In contrast to conventional therapies, with which median survival was mostly ≤12 months, among centers with expertise in this form of therapy, reported median survival for appropriately selected patients is 34 to 100 months.</p><p>Although limited, the following comparative studies are available:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 1514 patients with MPM reported to the National Cancer Database between 2004 and 2013, 379 underwent observation alone, 370 received chemotherapy only, 197 had surgical cytoreduction alone, 352 had CRS plus chemotherapy, and 216 underwent CRS/HIPEC [<a href="#rid10">10</a>]. In multivariate analysis, as compared with the CRS/HIPEC cohort, receipt of surgical cytoreduction alone, chemotherapy only, or observation were independently associated with inferior survival; in contrast, the group receiving surgical cytoreduction plus chemotherapy had a similar survival. The corresponding five-year overall survival rates for CRS/HIPEC, CRS/chemotherapy, CRS alone, chemotherapy alone, and observation were 52, 42, 22, 22, and 9 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based Dutch study of 566 patients diagnosed with MPM between 1993 and 2016 found that compared with best supportive care alone, improved survival was independently associated with the use of surgery (hazard ratio [HR] 0.33, 95% CI 0.23-0.48), HIPEC (HR for death 0.33, 95% CI 0.21-0.55), and systemic chemotherapy (HR 0.61, 95% CI 0.49-0.76) [<a href="#rid9">9</a>]. Two-year survival rates were 50 percent with CRS/HIPEC, but they were not significantly different with surgery plus systemic chemotherapy (44 percent, HR for death 1.115, 95% CI 0.867-1.435). By contrast, outcomes were significantly better for CRS/HIPEC compared with CRS alone (22 percent, HR for death 1.859, 95% CI 1.378-2.509), chemotherapy alone (18 percent, HR for death 1.843, 95% CI 1.450-2.341), and best supportive care and other forms of therapy (8 percent, HR for death 2.903, 95% CI 2.270-3.702).</p><p></p><p>For patients who are not candidates for CRS/HIPEC due to unresectable disease or medical comorbidities, systemic chemotherapy with contemporary pemetrexed-based regimens achieves response rates comparable to those seen in patients with pleural mesothelioma and is now commonly incorporated into some peritoneal mesothelioma treatment algorithms  (<a class="graphic graphic_algorithm graphicRef129848" href="/d/graphic/129848.html" rel="external">algorithm 1</a>). There are a small number of reports of immune checkpoint inhibitor immunotherapy in peritoneal mesothelioma; although the bulk of the data are in malignant pleural mesothelioma, with some early phase clinical trials included peritoneal as well as pleural disease. (See <a class="local">'Efficacy of systemic chemotherapy'</a> below.)</p><p class="headingAnchor" id="H135336274"><span class="h2">Cytoreductive surgery and intraperitoneal chemotherapy</span><span class="headingEndMark"> — </span>For selected patients with diffuse MPM, no extraperitoneal disease spread, a good performance status, and who can be predicted to achieve complete surgical cytoreduction based upon preoperative imaging, we recommend regional therapy using cytoreductive surgery (CRS) and HIPEC rather than systemic or intraperitoneal chemotherapy or surgical debulking alone. Outcomes are optimal when patients are referred to and treated in centers with expertise in the management of peritoneal surface malignancies. For patients who are not candidates for CRS/HIPEC, we suggest systemic chemotherapy rather than debulking surgery.</p><p>In the past, MPM was treated at most cancer centers with a combination of cytotoxic chemotherapy, palliative surgery, and in a few patients, total abdominal radiation, and median survival durations were uniformly approximately one year, and there were few, if any, five-year survivors [<a href="#rid2">2,7,13-16</a>]. (See <a class="local">'General treatment principles and historic evolution'</a> above.)</p><p>Although randomized trials have not been conducted, as the number of centers utilizing CRS/HIPEC has expanded, particularly over the last ten years, marked improvements in median survival for MPM ranging from 34 to 100 months have been reported in patients treated with CRS/HIPEC, with five-year survival rates from 29 to 59 percent [<a href="#rid2">2,9,10,17-22</a>]. Significant reductions in morbidity and mortality rates have also been achieved [<a href="#rid23">23</a>].</p><p>Results in contemporary series of patients treated with CRS/HIPEC are discussed in more detail below. (See <a class="local">'Results'</a> below.)</p><p class="headingAnchor" id="H3156095176"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>Briefly, the rationale for CRS/HIPEC therapy in MPM is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>MPM remains confined to the peritoneal cavity in the majority of cases. Because peritoneal implants are often superficial and do not invade underlying tissues deeply until the late stages, the disease is amenable to complete or near complete cytoreduction in over one-half of all patients undergoing exploration. The completeness of surgical cytoreduction is a major prognostic factor. (See <a class="local">'Patient selection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct intraperitoneal administration of chemotherapy permits a several-fold increase in drug concentration in the peritoneum compared with systemic administration. Despite this regional advantage, direct penetration into tumor tissue is limited to a few millimeters. This may be enhanced by heating the perfusate containing chemotherapy, but even so, this form of therapy is best restricted to small volume disease.</p><p></p><p>Additional detailed information on rationale for HIPEC is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/121546.html" rel="external">"Anesthesia for cytoreductive surgery with heated intraperitoneal chemotherapy", section on 'Hyperthermic intraperitoneal chemotherapy'</a>.)</p><p>Good results from CRS/HIPEC can be achieved with optimally selected patient populations and with treatment delivery in a center with expertise in these technically demanding procedures:</p><p class="bulletIndent1"><span class="glyph">●</span>This approach is best suited for patients with no evidence of extraperitoneal spread, a good performance status, and a disease burden that is amenable to cytoreduction to minimal residual disease (no deposits over 2 to 2.5 mm) [<a href="#rid24">24</a>]. It is unlikely that even a heated solution of chemotherapy could penetrate large tumor deposits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The favorable results (particularly in regard to treatment-related toxicity) achieved by international experts in the field may not be replicated in routine clinical practice. Patients with MPM should be managed at an institution with demonstrated experience in this therapy. The quality of the CRS is dependent upon the skills and level of experience of the surgeon [<a href="#rid25">25</a>]. Even at dedicated treatment centers, major morbidity is experienced by at least 30 percent of patients, the median hospital stay is 12 days, and the operative mortality rate is approximately 2 percent [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Guidance as to centers with expertise in treatment of peritoneal mesothelioma in the United States is available from the nonprofit <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.curemeso.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEWzdC0x4JbrC16vkq2k5iyq77hz7i193fFEsLz6U3Nvs&amp;TOPIC_ID=82913" target="_blank">Mesothelioma Applied Research Foundation (MARF)</a>.</p><p></p><p class="headingAnchor" id="H135336281"><span class="h3">Patient selection</span><span class="headingEndMark"> — </span>Several factors are associated with better outcomes after CRS and HIPEC, some of which are useful for stratifying patients into groups that are more or less likely to benefit from this aggressive approach. These include disease extent and depth of tumor invasion beyond the mesothelial surface, the predicted completeness of cytoreduction, histology (epithelioid better than sarcomatoid or biphasic), age (less than 60 better than older), the presence of preoperative thrombocytosis, and weight loss [<a href="#rid27">27-34</a>]. Female gender may also be independently associated with a better prognosis, with younger women (&lt;55 years of age) doing better than older women [<a href="#rid35">35</a>].</p><p>Results from the initial staging computed tomography (CT) scan can be used to predict the likelihood of complete surgical cytoreduction. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Radiographic imaging'</a>.)</p><p>The Washington Hospital Center team systematically scored findings on preoperative CT scans from 30 patients undergoing CRS and HIPEC for MPM, and identified features associated with adequacy of cytoreduction [<a href="#rid36">36</a>]. The presence of a &gt;5 cm mass in the epigastric region and loss of normal architecture of the small bowel and its mesentery (matted adjacent small bowel loops, distorted and thickened configuration, segmental small bowel obstruction, small bowel mesenteric vessels difficult to define due to obliteration of mesenteric fat) were the radiographic features that were most strongly associated with suboptimal cytoreduction. Patients who had neither of these two findings had a 94 percent probability of adequate cytoreduction (defined as all residual tumor nodules &lt;2.5 cm in diameter), while no patient with both findings had a successful surgical cytoreduction.</p><p>Others have identified unfavorable radiographic imaging findings, including large volume upper abdominal disease and disease that is visible in the small bowel as reducing the likelihood of complete surgical cytoreduction [<a href="#rid37">37</a>].</p><p>Radiographic criteria such as these are used to select patients with a peritoneal surface malignancy who are most likely to benefit from aggressive surgical debulking and HIPEC. Other factors are derived intraoperatively.</p><p>The Sugarbaker group uses four preoperative and intraoperative features to select patients for combined treatment [<a href="#rid38">38,39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative contrast (oral and IV)-enhanced CT of the chest, abdomen, and pelvis – In addition to excluding liver or other systemic metastases, the finding of segmental obstruction of the small bowel and tumor nodules &gt;5 cm in diameter on small bowel surfaces or directly adjacent to the small bowel mesentery in the jejunum or upper ileum predict a poor outcome from CRS and HIPEC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathology – Noninvasive malignancies such as mesothelioma are more likely to be made visibly disease-free through a peritonectomy procedure and are less likely that other invasive histologies (eg, colonic adenocarcinoma) to have spread to regional nodes, liver, or other systemic sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two other clinical indices, the peritoneal cancer index (PCI; a quantitative prognostic indicator derived from the size and distribution of peritoneal surface nodules), and the completeness of cytoreduction score (ie, size of persisting nodules after maximal cytoreduction) are derived intraoperatively [<a href="#rid40">40,41</a>].</p><p></p><p>Laparoscopy may also be used to predict which patients are likely to have a complete surgical cytoreduction during a subsequent laparotomy [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H135336288"><span class="h3">Technique</span><span class="headingEndMark"> — </span>Intraoperative procedures that may be used to achieve complete gross cytoreduction include omentectomy, splenectomy, small and large bowel resection, peritonectomy, hysterectomy, salpingectomy, oophorectomy, and low anterior resection. Implants on the capsule of the liver or other solid viscera are usually treated by electrical or argon beam coagulation or some other type of electrofulguration.</p><p>HIPEC is done selectively and may be omitted if CRS has been suboptimal. The degree to which surgical cytoreduction versus intraperitoneal chemotherapy contributes to patient outcomes is unclear.</p><p>The treatment parameters for HIPEC (type of chemotherapy, degree of hyperthermia, and duration of perfusion) vary considerably from one institution to another. (See  <a class="medical medical_review" href="/d/html/121546.html" rel="external">"Anesthesia for cytoreductive surgery with heated intraperitoneal chemotherapy", section on 'Infusion procedure'</a>.)</p><p>Although many chemotherapy agents have been used for HIPEC  (<a class="graphic graphic_table graphicRef129409" href="/d/graphic/129409.html" rel="external">table 3</a>), the most commonly used for peritoneal mesothelioma are <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> or <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid43">43</a>]. There are scant data to support any specific regimen over another:</p><p class="bulletIndent1"><span class="glyph">●</span>Two retrospective reports suggest that patients treated with intraperitoneal <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> via HIPEC may have superior survival compared with those treated with <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> [<a href="#rid44">44,45</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study has reported outcomes that are similar to others in 19 patients with MPM (four had progressive benign multicystic mesothelioma) treated with CRS and HIPEC using <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective database series of 249 patients undergoing CRS and HIPEC for peritoneal mesothelioma concluded that there was no difference in outcomes for any of the single chemotherapy agents, but that overall survival was better with two drugs as compared with one [<a href="#rid47">47</a>].</p><p></p><p>Interpretation of all of these reports is limited by their retrospective nature. The bottom line is that there are no consistent data favoring one type of chemotherapy over another. A standard approach includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>After maximal surgical debulking, large bore catheters are placed within the peritoneal cavity and connected to an extracorporeal recirculating perfusion circuit consisting of a reservoir, roller pump, and heat exchanger.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Four to 6 L of perfusate containing <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> at a dose of 40 mg or <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> 75 mg/m<sup>2</sup> (based on ideal body weight) are circulated through the peritoneal cavity for 90 minutes. The perfusate is warmed to achieve target intraperitoneal temperatures between 40 and 42ºC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some leave catheters in place for postoperative continuation of intraperitoneal chemotherapy, but most do not [<a href="#rid27">27,48,49</a>].</p><p></p><p>Additional information on the technical aspects of delivering intraoperative HIPEC is provided elsewhere. (See  <a class="medical medical_review" href="/d/html/121546.html" rel="external">"Anesthesia for cytoreductive surgery with heated intraperitoneal chemotherapy", section on 'Infusion procedure'</a>.)</p><p class="headingAnchor" id="H135336295"><span class="h3">Results</span><span class="headingEndMark"> — </span>Over the past 30 years, there have been a large number of single center and two multicenter reports that detail the outcomes of patients treated with operative resection (CRS) and HIPEC or EPIC for MPM. The median overall survival ranges from 30 to 92 months, and this large range most likely reflects variations between centers with respect to patient selection criteria [<a href="#rid12">12,18,27,50-52</a>]. Despite the absence of randomized controlled trials demonstrating a benefit of CRS and HIPEC, this approach has been accepted as first-line treatment for selected MPM patients who have a good performance status and a disease burden that is amenable to complete (or near complete) cytoreduction. Multiple single institution studies have consistently shown favorable survival with this approach as compared with historical survival data from treatment with systemic chemotherapy alone or in conjunction with palliative surgery  (<a class="graphic graphic_figure graphicRef95960" href="/d/graphic/95960.html" rel="external">figure 1</a>). The overall median survival durations for patients treated with CRS and HIPEC were 53 and 38 months in two large multi-center studies [<a href="#rid45">45,53</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The largest multi-institutional registry combining retrospective data on patients with MPM treated with CRS and HIPEC at 29 clinical centers worldwide included 405 patients with MPM; a variety of intraperitoneal chemotherapeutic agents were utilized during HIPEC including <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> C, and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> [<a href="#rid53">53</a>]. The median actuarial overall survival was 53 months with one-, three-, and five-year survival rates of 81, 60, and 47 percent, respectively. Prognostic factors associated with improved survival on multivariate analysis were epithelioid histologic subtype, absence of lymph node metastases, complete or near complete resection (ie, completeness of cytoreduction score [CC] 0 or 1  (<a class="graphic graphic_table graphicRef95958" href="/d/graphic/95958.html" rel="external">table 4</a>)) [<a href="#rid54">54</a>], and the use of HIPEC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second multi-institutional report that included 211 patients treated at three centers in the United States (which were not part of the previous study) showed an actuarial overall survival of 38 months and 5- and 10-year survival rates of 41 and 26 percent, respectively [<a href="#rid45">45</a>]. All patients underwent CRS and HIPEC using either <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> C. Prognostic factors associated with improved survival were age less than 60 years, complete or near complete gross resection (CC-0 or 1,  (<a class="graphic graphic_table graphicRef95958" href="/d/graphic/95958.html" rel="external">table 4</a>)), low versus high histologic grade, and the use of cisplatin versus mitomycin C  (<a class="graphic graphic_figure graphicRef95961" href="/d/graphic/95961.html" rel="external">figure 2</a>). Although retrospective, the data suggested a better outcome of HIPEC using cisplatin in patients with this disease; interestingly, the benefit was most marked in those who had a CC-0 or 1, and there was no benefit to HIPEC with either agent in patients who had a suboptimal surgical cytoreduction (CC &gt;2  (<a class="graphic graphic_table graphicRef95958" href="/d/graphic/95958.html" rel="external">table 4</a>)). This observation confirmed a prior series that showed a trend towards improved survival with cisplatin rather than mitomycin [<a href="#rid44">44</a>].</p><p></p><p>Results from these reports and several contemporary single center studies of CRS and HIPEC are outlined in the table  (<a class="graphic graphic_table graphicRef64317" href="/d/graphic/64317.html" rel="external">table 5</a>) [<a href="#rid19">19,45,53,55-58</a>]. These results compare favorably with other, mostly older, reports detailing the efficacy of CRS/HIPEC and the factors that influence outcomes, including age under 60, incomplete surgical cytoreduction, sarcomatoid growth pattern, and degree of tissue invasion [<a href="#rid27">27,29,32,59</a>].</p><p>Over time, improvements in patient selection seems to have resulted in better outcomes from CRS/HIPEC. This was suggested in an analysis of 1591 patients diagnosed with MPM between 1973 and 2010 derived from the Surveillance, Epidemiology, and End Results database [<a href="#rid60">60</a>]. A number of parameters were associated with a greater risk of shortened survival, including advancing age, male gender, histology (biphasic or sarcomatoid versus epithelioid), and extent of disease. Surgical resection was associated with improved survival overall and survival after surgical resection improved over time. However, 57 percent of individuals diagnosed with MPM during the most recent time interval (2006 to 2010) did not undergo any time of surgical resection, suggesting that many individuals who may be good candidates for surgical resection are not presented with this option.</p><p>The benefits of CRS/HIPEC were confirmed in a systematic review of 20 publications totaling 1047 patients with MPM [<a href="#rid18">18</a>]. Complete or near complete surgical cytoreduction (CC-0 or CC-1  (<a class="graphic graphic_table graphicRef95958" href="/d/graphic/95958.html" rel="external">table 4</a>)) was achieved in 67 percent of patients, and the estimated five-year survival was 42 percent. Treatment factors associated with improved survival included the use of EPIC and the use of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> alone or in combination during HIPEC or EPIC. Some of the publications included in the meta-analysis were sequential reports from one institution, which may have included overlapping cohorts of patients.</p><p>Several studies have shown that HIPEC can also palliate malignant ascites in patients with MPM, even in those who have suboptimal or no surgical cytoreduction [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H3920502587"><span class="h4">Treatment of recurrent disease</span><span class="headingEndMark"> — </span>For patients with recurrence after initial CRS/HIPEC, repeat CRS and HIPEC in selected patients can result in long-term survival, although patient selection is critical [<a href="#rid63">63-65</a>]. A study from the Washington Hospital Center reported the outcomes of 44 patients out of 205 with MPM who underwent a second CRS and HIPEC [<a href="#rid63">63</a>]. Median overall survival was 54 months in those undergoing a second CRS and HIPEC versus 77 months for those after initial CRS and HIPEC. Notably, the ability to achieve a complete or near complete (CC-0 or CC-1  (<a class="graphic graphic_table graphicRef95958" href="/d/graphic/95958.html" rel="external">table 4</a>)) resection was significantly lower in patients undergoing a second CRS and HIPEC.</p><p>In an updated report from the same center, the authors noted that patients with no or minimal symptoms and those with limited radiographic evidence of recurrent disease had longer survival than those with abdominal pain or distention or those who had radiographic evidence of solid tumor masses in the abdomen [<a href="#rid66">66</a>]. These and other data [<a href="#rid64">64</a>] highlight the need for careful patient selection.</p><p class="headingAnchor" id="H135336302"><span class="h3">Treatment-related toxicity</span><span class="headingEndMark"> — </span>In general, with improvements in patient selection, operative technique, and postoperative management, the mortality associated with CRS and HIPEC has decreased, and overall survival has increased over the past 25 years. In expert hands, CRS and HIPEC treatment is associated with an operative mortality rate that ranges from 0 to 8 percent, and rates of serious perioperative morbidity are between 10 and 45 percent. Complications related to chemotherapy are almost invariably related to myelosuppression, while complications related to laparotomy and CRS include fistula, bleeding, wound infection, and sepsis.</p><p>The range of findings can be illustrated by the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>Passot et al have reported a 25-year institutional experience with CRS and HIPEC in 1125 patients with a variety of peritoneal malignancies (84 [8 percent] with MPM) [<a href="#rid12">12</a>]. There were some significant trends over the last 10 years of the experience (which included almost 900 patients), such as selection of patients with a lower PCI, an increased proportion of patients undergoing a complete or near complete clinical response, and improved survival. Of note, while operative time and overall complication rates did not change, the operative mortality decreased significantly from 5 to 2 percent over time. These data reflect a general improvement in patient selection and, perhaps, an improvement in perioperative management that has translated into generally better outcomes. Complications were most commonly intra-abdominal events (abscess or fistula), observed in 20 percent of patients, followed by cardiovascular and respiratory events, each occurring in approximately 15 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a report from the Sugarbaker group, treatment-related toxicity was categorized as grade 1, no intervention reported for resolution; grade 2, medical treatment sufficient for resolution; grade 3, invasive (eg, radiologic or transfusional) intervention required for resolution; grade 4, urgent definitive intervention (eg, return to the operating room or to the surgical intensive care unit) required for resolution [<a href="#rid48">48</a>]. Grade 3 or 4 morbidity rates were 27 and 14 percent, respectively. Low hemoglobin level was responsible for 26 percent of all grade 3 toxicities, while central line sepsis and urinary tract infection accounted for 17 and 13 percent, respectively. Postoperative bleeding requiring a return to the operating room accounted for 38 percent of the grade 4 adverse events, and respiratory failure requiring intubation was responsible for 22 percent. Risk factors for grade 4 morbidity included primary colonic anastomosis, more than four peritonectomy procedures, and operative duration over seven hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term consequences seem to be limited; however, in a series of 42 patients (two with MPM) undergoing CRS and HIPEC at a high-volume center in Toronto, Hamilton et al reported a 33 percent major complication rate, which was associated with a significantly longer average length of hospital stay compared with those without complications (35 versus 13 days, respectively) [<a href="#rid67">67</a>]. Despite this, the authors noted no differences in any measured quality of life parameter between the groups at six months after treatment, suggesting that there are limited long-term consequences to perioperative morbidity after CRS and HIPEC. This observation has been reported by others [<a href="#rid68">68</a>].</p><p></p><p>These data are derived from groups with demonstrated experience and expertise in the procedure, and they may not be replicated in routine clinical practice. However, analysis of a large group of experienced centers through the American College of Surgeons National Surgical Quality Improvement Project (NSQIP) reveals that CRS/HIPEC is not associated with higher complication rates than other surgical procedures. A study of the NSQIP database demonstrates overall 30-day mortality was lower in CRS/HIPEC compared with Whipple, right lobe hepatectomy, esophagectomy, and trisegmental hepatectomy [<a href="#rid23">23</a>]. Guidance as to centers with expertise in treatment of peritoneal mesothelioma is available from the nonprofit <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.curemeso.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEWzdC0x4JbrC16vkq2k5iyq77hz7i193fFEsLz6U3Nvs&amp;TOPIC_ID=82913" target="_blank">Mesothelioma Applied Research Foundation (MARF)</a>.</p><p class="headingAnchor" id="H109023551"><span class="h3">Contribution of systemic therapy</span><span class="headingEndMark"> — </span>The role of systemic chemotherapy in conjunction with CRS plus HIPEC is uncertain, and there is no consensus on when or if it should be used; these decisions must be individualized. For patients in whom the timing of operative CRS and HIPEC must be delayed, we suggest a course of initial systemic chemotherapy until the definitive operation can be performed. Others suggest the use of initial systemic chemotherapy for all biphasic/sarcomatoid histologies and for epithelioid histology cases in which incomplete cytoreduction is predicted, with CRS/HIPEC offered to those who subsequently convert to a radiographic assessment of "complete cytoreduction predicted"  (<a class="graphic graphic_algorithm graphicRef129848" href="/d/graphic/129848.html" rel="external">algorithm 1</a>) [<a href="#rid69">69</a>]. (See <a class="local">'Patient selection'</a> above.)</p><p>If upfront chemotherapy is chosen, we suggest a <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> plus platinum-containing regimen, similar to that used for nonresectable disease. Notably, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> should not be used in the neoadjuvant setting due to the high likelihood of poor wound healing, concerns about intra-abdominal bleeding or perforation, and the long half-life of that agent. (See <a class="local">'Efficacy of systemic chemotherapy'</a> below.)</p><p>After CRS and HIPEC, we suggest systemic chemotherapy as consolidation treatment if high-risk histopathologic features are present, such as the presence of deep tissue invasion, biphasic histology, or baseline thrombocytosis. For patients with optimal cytoreduction and no histopathologic features that would suggest increased risk of early recurrence, no systemic therapy is recommended.</p><p>The utility of adjuvant or neoadjuvant systemic chemotherapy has not been formally addressed in prospective clinical trials. The following data are available from retrospective analyses:</p><p class="bulletIndent1"><span class="glyph">●</span>Using the United States National Cancer Database, investigators compared outcomes between those patients receiving chemotherapy only, surgery only, or surgery with adjuvant or neoadjuvant therapy [<a href="#rid70">70</a>]. Surgery was rigorously defined as debulking or radical surgery with a report of complete cytoreduction. Of 1136 patients, 55 (3.2 percent) had neoadjuvant chemotherapy prior to complete cytoreduction, 228 (13.1 percent) had adjuvant chemotherapy following complete cytoreduction, and 684 (39.3 percent) patients had surgery alone. Long-term outcomes were similar among all three groups, with patients receiving any chemotherapy appearing to do better, at least in the first year. However, it is plausible that patients with complete cytoreduction who did not receive additional therapy had either comorbidities or surgical morbidities that may have affected their ability to receive perioperative chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Investigators at the National Cancer Institute of Milan reported outcomes in 116 MPM patients, some of whom received neoadjuvant and/or adjuvant systemic chemotherapy in addition to HIPEC [<a href="#rid71">71</a>]. Although the criteria used to select patients for perioperative chemotherapy were not well defined, there was no association between use of chemotherapy and completeness of cytoreduction, operative morbidity, or survival in the cohort of 60 patients who received neoadjuvant chemotherapy; there was no hint of a survival benefit from the use of postoperative chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, a retrospective review of 126 patients with diffuse MPM treated at one of 20 French centers from 1991 to 2014 with CRS plus HIPEC included cohorts treated with neoadjuvant (n = 42), adjuvant (n = 16), perioperative (n = 16), or no chemotherapy (n = 48); as with the Milan series, the criteria used to select patients for a specific approach were not specified [<a href="#rid72">72</a>]. Contemporary pemetrexed-based regimens were administered in only 62 percent of patients. There was no significant difference in survival between patients receiving no chemotherapy and those receiving either adjuvant alone or perioperative chemotherapy (five-year overall survival 56, 67, and 62 percent, respectively), while patients receiving neoadjuvant therapy had a lower five-year survival rate (40 percent). On multivariate analysis, the sole factor independently associated with better overall survival was the lack of neoadjuvant therapy (HR 2.2, p = 0.033). Adjuvant chemotherapy (p = 0.006) and treatment period after 2005 (p = 0.030; after the approval of <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>) were associated with an improved progression-free survival on univariate, but not multivariate, analysis.</p><p></p><p class="bulletIndent1">Given the limited sample size and retrospective nature of this series, these data should be interpreted cautiously. The authors speculated that neoadjuvant chemotherapy may have been offered more frequently to those patients with more aggressive disease, while patients who had a good response to neoadjuvant treatment may have been more likely to later receive adjuvant chemotherapy and were, thus, included in the perioperative, rather than the neoadjuvant, group. Alternatively, these data may suggest a lower sensitivity to chemotherapy in unresected patients with bulkier disease. The authors also concluded that the longer progression-free survival in patients who received adjuvant chemotherapy, especially contemporary regimens, suggests that this should be considered to delay recurrence and potentially improve survival.</p><p></p><p class="headingAnchor" id="H3452112192"><span class="h2">Approach to patients who are not candidates for CRS/HIPEC</span><span class="headingEndMark"> — </span>For patients who are not candidates for cytoreductive surgery (CRS)/hyperthermic intraoperative peritoneal perfusion with chemotherapy (HIPEC), we suggest systemic chemotherapy rather than debulking surgery. For most patients, we suggest a pemetrexed-containing regimen over other chemotherapy options. <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef67209" href="/d/graphic/67209.html" rel="external">table 6</a>) is an active regimen if the patient's performance status and general health are adequate to tolerate it. Particularly in the palliative setting, pemetrexed plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>  (<a class="graphic graphic_table graphicRef81778" href="/d/graphic/81778.html" rel="external">table 7</a>) might be preferred given that it achieves similar results with less toxicity. Another option for first-line treatment, for patients who can tolerate it, is the addition of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> to pemetrexed plus a platinum agent. When the chemotherapy regimen includes pemetrexed, concurrent supplementation with <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a> and <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> is needed to reduce toxicity. (See <a class="local">'Pemetrexed-based regimens'</a> below and  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Pemetrexed plus cisplatin'</a>.)</p><p class="headingAnchor" id="H135336309"><span class="h3">Efficacy of systemic chemotherapy</span></p><p class="headingAnchor" id="H1668514668"><span class="h4">Peritoneal versus pleural mesothelioma</span><span class="headingEndMark"> — </span>Trials that have been conducted exclusively in patients with peritoneal mesothelioma are quite uncommon, and assumptions about the activity of various chemotherapeutic agents for peritoneal mesothelioma are often extrapolated from the more extensive data derived from patients with pleural mesothelioma. It is generally assumed (and supported by uncontrolled data [<a href="#rid73">73</a>]) that the efficacy of most systemic chemotherapy is similar in both disease sites, despite variations in gene expression profiles that suggest different pathophysiology for pleural and peritoneal mesothelioma.</p><p>Most clinical trials that evaluate new drugs or drug combinations in mesothelioma specifically exclude patients with peritoneal mesothelioma. Those trials that do permit the enrollment of mesothelioma disease sites other than the pleura generally include few peritoneal mesothelioma subjects due to the rarity of peritoneal mesothelioma and the standard eligibility requirement for radiologically measurable disease, which can be difficult to determine in the peritoneal cavity. Furthermore, trials may not report results in patients with peritoneal mesothelioma separately due to the small numbers.</p><p>Prospective trials, such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DNCT05001880%26cntry%3D%26state%3D%26city%3D%26dist%3D&amp;token=y9Ko1yE34GGrP5bydgofpF1u3LkWEHWZsTp%2BpdQ9rrCOdI%2F4qCMywgrcdz1cxY9j3sn6msm70EiRlTeREUg5WDuZn51LC7L69CSizKnUUQFD02iDz9V7FdujfXGEHFwq&amp;TOPIC_ID=82913" target="_blank">Alliance A092001, a randomized trial of pemetrexed plus carboplatin and bevacizumab, with or without atezolizumab</a>, should enhance our understanding of the activity of both chemotherapy and immunotherapy at this disease site.</p><p class="headingAnchor" id="H1537477278"><span class="h4">Choice of regimen</span><span class="headingEndMark"> — </span>A meta-analysis of clinical trials reported between 1965 and 2001 determined that <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> was the single most active cytotoxic agent against mesothelioma [<a href="#rid74">74</a>]. Single-agent cisplatin was used as the control arm of two large phase III trials in pleural mesothelioma [<a href="#rid75">75,76</a>], although in clinical practice, it is never administered as monotherapy outside of a clinical trial setting. The addition of cisplatin to other active single agents, such as <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, <a class="drug drug_general" data-topicid="10087" href="/d/drug information/10087.html" rel="external">raltitrexed</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, or <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, increases the objective response rate [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Subsequent-line treatment'</a>.)</p><p>The antifolates are currently considered the most active class of drugs against mesothelioma. <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a>, an antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, is the first and only drug approved in the United States for the treatment of mesothelioma. Approval was based upon a single-blind, placebo-controlled, randomized phase III study in which 456 patients with pleural mesothelioma were randomly assigned to pemetrexed, 500 mg/m<sup>2</sup> every 21 days plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, 75 mg/m<sup>2</sup>, or placebo with cisplatin. Those patients who received pemetrexed plus cisplatin achieved a significantly superior overall survival (12.1 versus 9.3 months, respectively; p = 0.020), longer time to disease progression (5.7 versus 3.9 months, p = 0.001), and higher objective response rate (41 versus 17 percent) [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Pemetrexed plus cisplatin'</a>.)</p><p>The following discussion will focus on data obtained in patients with MPM. General principles of systemic therapy for pleural and other forms of mesothelioma are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H1398023172"><span class="h5">Pemetrexed-based regimens</span><span class="headingEndMark"> — </span>The utility of <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> in patients with MPM has principally been demonstrated in analyses of the Pemetrexed Expanded Access Program, both in the United States and internationally [<a href="#rid78">78,79</a>]. Prospective phase II or III clinical trials of this regimen have not been conducted in patients with peritoneal mesothelioma, however.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemetrexed</strong><strong> plus </strong><strong>cisplatin</strong> – Systemic chemotherapy with <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> has been a cornerstone of treatment for advanced pleural mesothelioma since 2004 when the EMPHACIS trial demonstrated better outcomes for this combination compared with cisplatin alone. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Pemetrexed plus cisplatin'</a>.)</p><p></p><p class="bulletIndent1">The available data suggest that the efficacy of <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is comparable in peritoneal mesothelioma to that seen in malignant pleural mesothelioma, and the regimen has generally been well tolerated. Of the 1056 mesothelioma patients enrolled in the United States Expanded Access Program prior to US Food and Drug Administration (FDA) approval of pemetrexed, 98 (9.3 percent) had peritoneal primary sites. Fifty-seven were previously treated, and 38 were chemotherapy-naive. Patients received either pemetrexed alone (500 m<sup>g</sup>/m<sup>2</sup> every 21 days, n = 32) or the same dose of pemetrexed in combination with cisplatin (75 m<sup>g</sup>/m<sup>2</sup> every 21 days, n = 66) for six cycles or until disease progression  (<a class="graphic graphic_table graphicRef67209" href="/d/graphic/67209.html" rel="external">table 6</a>) [<a href="#rid78">78</a>]. <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> (350 to 600 mcg daily) and <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a> (1000 mcg intramuscularly one to two weeks before the first dose, then every nine weeks) were administered to all patients. Vitamin supplementation improves response to therapy and reduces treatment-related toxicity.</p><p></p><p class="bulletIndent1">Since measurable disease was not required for enrollment, only 73 patients with MPM were evaluable for response (28 chemotherapy-naive and 43 previously treated). Twenty-six received single-agent <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> and 47 were given the two-drug combination. There were 19 objective responses (four complete) for an overall response rate of 26 percent; another 45 percent had stable disease. The disease control rate (objective responses plus stable disease) was 71 percent, and similar objective response rates were achieved in the previously-treated and chemotherapy-naive patients. Median overall survival for previously-treated patients was 13.1 months; it had not been reached at the time of the analysis for chemotherapy-naive patients. As expected, both response rate (29 versus 19 percent) and median survival (13.1 versus 8.7 months) were higher with the pemetrexed doublet than with pemetrexed alone (although the survival outcomes could easily reflect patient selection in this nonrandomized study), and in both cases, the results were comparable with those seen in pleural mesothelioma. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Pemetrexed plus cisplatin'</a>.)</p><p></p><p class="bulletIndent1">Treatment appeared to be well tolerated. The safety database of 1056 patients did not distinguish between patients with pleural or peritoneal mesothelioma, so it is uncertain whether there were any distinct toxicities in the peritoneal subset. The safety analysis in this trial relied on investigator reported serious adverse events, and thus the true rate of toxicity derived from analysis of experience in the Expanded Access Program is likely much greater than reported. Grade 3 or 4 hematologic toxicity (primarily anemia) was documented in only 2 percent of patients and neutropenia, in less than 1 percent. The most common grade 3 or 4 nonhematologic toxicities were dehydration (7 percent), nausea (5 percent), and vomiting (5 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemetrexed</strong><strong> plus </strong><strong>carboplatin</strong> – <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">Carboplatin</a> is often substituted for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, particularly in the palliative setting and in older patients [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Pemetrexed plus carboplatin'</a>.)</p><p></p><p class="bulletIndent1">In the International <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> Expanded Access Program, 29 evaluable patients with peritoneal mesothelioma received pemetrexed 500 mg/m<sup>2</sup> and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, dosed at an area under the concentration X time curve of 5 mg/mL x min, supplemented with standard <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a>, folate, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>  (<a class="graphic graphic_table graphicRef81778" href="/d/graphic/81778.html" rel="external">table 7</a>) [<a href="#rid79">79</a>]. Seven patients (24 percent) had objective responses (one complete), and 52 percent had stable disease. These results are comparable to those achieved with pemetrexed and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemetrexed</strong><strong> plus </strong><strong>cisplatin</strong><strong> and </strong><strong>bevacizumab</strong> – The addition of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> to the pemetrexed-cisplatin regimen improved both progression-free and overall survival compared with <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> without bevacizumab in the large phase III MAPS trial conducted exclusively in patients with malignant pleural mesothelioma [<a href="#rid80">80</a>]. It is reasonable to extrapolate this experience to patients with MPM, although care should be taken in patient selection for bevacizumab (patients should have no poorly controlled hypertension, deep venous thrombosis, recent or planned surgery, or viscus perforation, and they must have a good performance status). This trial is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Addition of bevacizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemetrexed</strong><strong> plus </strong><strong>gemcitabine</strong> – One of the largest prospective multicenter chemotherapy experiences reported in peritoneal mesothelioma evaluated the combination of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> (1250 mg/m<sup>2</sup> on days 1 and 8) plus <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> (500 mg/m<sup>2</sup> on day 8, before gemcitabine) in 20 chemotherapy-naive but highly selected patients with peritoneal mesothelioma [<a href="#rid81">81</a>]. A median of six cycles were delivered. There were three partial responses (response rate 15 percent), and 35 percent had stable disease, for a disease control rate of 50 percent. Median time to disease progression was 10.4 months, median overall survival was 26.8 months, and one-year survival was 67.5 percent. However, hematologic toxicity was substantial, and included grade 3 or 4 neutropenia in 60 percent, febrile neutropenia in 10 percent, and grade 4 anemia in 5 percent. The most common grade 3 and 4 nonhematologic toxicities included fatigue in 20 percent, and constipation, vomiting, and dehydration, each in 10 percent of patients.</p><p></p><p class="bulletIndent1">Importantly, this phase II trial was conducted in patients with predominantly pleural mesothelioma, and this report covered the 20 patients with peritoneal mesothelioma who were allowed to enroll, but without a statistical plan for separate analysis. As such, the data should be considered the equivalent of an observational study. We do not consider this a valid regimen for peritoneal mesothelioma given its toxicity and the low response rate (15 percent), which is comparable with that which can be achieved using <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> alone, and lower than would be expected with pemetrexed plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>.</p><p></p><p class="headingAnchor" id="H135336337"><span class="h5">Cisplatin plus irinotecan</span><span class="headingEndMark"> — </span>Responses have also been described with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> administered intraperitoneally or IV, in combination with IV <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> in a retrospective single-institution series [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H2354825404"><span class="h5">Other regimens</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is an active regimen in pleural mesothelioma, but data are not available in patients with a peritoneal primary site [<a href="#rid77">77</a>]. Similarly, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a> has a 24 percent single agent response rate in the front-line setting [<a href="#rid83">83</a>] and a 16 percent response rate in previously-treated pleural mesothelioma patients [<a href="#rid84">84</a>]. Whether these data are applicable to peritoneal patients is unclear, but the drugs are often used.</p><p class="headingAnchor" id="H3335557124"><span class="h5">Molecularly targeted therapy</span><span class="headingEndMark"> — </span>Preclinical data suggest a possible role for phosphatidylinositol-3-kinase (P13k) and inhibitors of the mechanistic (previously called mammalian) target of rapamycin signaling pathway in the malignant phenotype of diffuse MPM [<a href="#rid85">85</a>]; phase I and II trials of agents that target these pathways are ongoing.</p><p>Data on novel molecular pathways in mesothelioma (eg, rearrangements in the anaplastic lymphoma kinase gene [<a href="#rid86">86</a>]) are emerging, and they may have implications for future therapy using agents that target these abnormalities. Data on agents that target novel molecular pathways in mesothelioma, including mesothelin and vascular endothelial growth factor pathways, as well as inhibitors of histone deacetylase and focal adhesion kinase, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Investigational therapies'</a>.)</p><p class="headingAnchor" id="H2138378240"><span class="h3">Immunotherapy</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors, immunomodulatory antibodies that are used to enhance the antitumor activity of the immune system are now in routine use in multiple solid tumor types, including pleural mesothelioma. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>The role of immunotherapy in peritoneal mesothelioma is evolving, but given its approval for pleural mesothelioma, many clinicians are using it for peritoneal primaries, despite persisting questions as to whether data in pleural mesothelioma can always be extrapolated to the peritoneal disease site.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural mesothelioma</strong> – It is clear that immune checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) receptor alone or in combination with agents that inhibit a second immune checkpoint, cytotoxic T-lymphocyte antigen-4 (CTLA-4), have activity in pleural mesothelioma (see  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Immunotherapy'</a>). Briefly:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, both inhibitors of the PD-1 pathway, are both active agents in advanced pretreated disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The MAPS2 trial demonstrated a benefit for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus the CTLA-4 inhibitor <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> over nivolumab alone for second- or third-line therapy of advanced pretreated pleural mesothelioma [<a href="#rid87">87</a>]. None of the patients on this trial had a peritoneal primary site.</p><p></p><p class="bulletIndent2">On the other hand, a progression-free and overall survival benefit for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone versus placebo in patients previously treated with a first-line platinum-based chemotherapy regimen was shown in the CONFIRM trial [<a href="#rid88">88</a>]. In the CONFIRM trial, 5 percent of the enrollees (16 of 332) had an extrapleural site, but outcomes were not stratified according to primary site.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Efficacy was also shown for combined <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in treatment-naive patients in the CheckMate 743 trial, although the survival benefit appeared to be limited to those with nonepithelioid (ie, biphasic, sarcomatoid) histology [<a href="#rid89">89</a>], Largely based on these results, the combination of nivolumab plus ipilimumab was approved by the FDA for unresectable pleural mesothelioma in October 2020 [<a href="#rid90">90,91</a>], and the National Comprehensive Cancer Network (NCCN) considers this the preferred initial option for patients with nonepithelioid (ie, biphasic, sarcomatoid) tumors. None of the patients enrolled on this trial had a peritoneal primary site.</p><p></p><p class="bulletIndent1">An important point is that not all patient subgroups benefit equally from immunotherapy. In pleural mesothelioma, the benefit for first-line immunotherapy seems strongest in patients with nonepithelial tumors, while the majority of peritoneal mesotheliomas are epithelial. The role of PD-L1 expression or other biomarkers in selecting appropriate candidates for immune checkpoint inhibitor immunotherapy is incompletely understood. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Nonepithelioid histology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peritoneal mesothelioma</strong> – Given the relative lack of data in patients with a peritoneal primary, and concerns about benefit being limited to those with nonepithelioid histology in pleural mesothelioma, in our view, the available data are insufficient to conclude that immunotherapy using a checkpoint inhibitor alone or in combination (ie, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) is clearly superior to chemotherapy for first-line therapy for peritoneal mesothelioma patients; however, it may be a reasonable option for second-line therapy and beyond. There are no consensus-based guidelines from the NCCN or elsewhere that cover immunotherapy for peritoneal mesothelioma.</p><p></p><p class="bulletIndent1">Only limited data on the efficacy of immune checkpoint inhibitor immunotherapy are available from small numbers of patients with peritoneal mesothelioma:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">Tremelimumab</a>, a monoclonal antibody that targets CTLA-4, was evaluated in a 571-patient, double-blind, placebo-controlled, randomized phase IIb trial (DETERMINE) in patients with previously treated pleural or peritoneal (n = 26) mesothelioma. Unfortunately, there was no statistically significant difference in overall survival between the tremelimumab and placebo groups (HR 0.92, p = 0.41), and too few events to evaluate outcomes in the peritoneal subgroup separately [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PD-1 and its ligand (PD-L1) may be more appropriate targets than CTLA-4 in peritoneal mesothelioma, although definitive conclusions are limited by the small numbers of treated patients in both preclinical and clinical series. A few small clinical trials to date have evaluated PD-1 and PD-L1 inhibitors in patients with peritoneal mesothelioma:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the phase Ib JAVELIN trial, 53 patients with pleural or peritoneal mesothelioma who had progressed after platinum and <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> treatment (including 20 patients who had received three or more lines of therapy) were treated with <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>, a monoclonal antibody that targets PD-L1 [<a href="#rid93">93</a>]. Five patients had a confirmed objective response (9 percent), and responses were durable (median 15.2 months). Using a PD-L1 expression cutoff of 5 percent or greater to define PD-L1-positive tumors, the investigators observed a higher response rate in PD-L1-positive tumors (3 of 16 [19 percent]) than in PD-L1-negative tumors (2 of 27 [7 percent]). Unfortunately, no conclusions can be drawn about the activity of avelumab in the peritoneal mesothelioma subset, as the number of peritoneal patients was not reported, and PD-L1 expression and treatment outcomes were not analyzed by disease site.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A phase II trial evaluated the monoclonal antibody <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, which targets PD-1, in 64 previously treated mesothelioma patients, including eight with peritoneal mesothelioma. All patients had received no more than two prior lines of cytotoxic chemotherapy, which must have included <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> and a platinum. Although the response rate was greater in the pleural than in the peritoneal patients (20 versus 13 percent, respectively), PD-L1 expression was more common in the peritoneal subset. Only 25 percent of peritoneal patients were PD-L1 negative (defined as less than 1 percent expression), 50 percent were PD-L1 low (defined as 1 to 49 percent expression), and 25 percent were PD-L1 high (greater than or equal to 50 percent expression) [<a href="#rid94">94,95</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The NIBIT-MESO-1 trial included patients with either pleural or peritoneal mesothelioma, including both pretreated and treatment-naïve patients. Only two (5 percent) patients with peritoneal mesothelioma were enrolled, receiving combination <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> and <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a>; the combination appeared active, however, results were not reported separately from pleural disease [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Immunotherapy'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Potential benefit for the combination of <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a>, a humanized monoclonal antibody that binds to PD-L1, plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), was suggested in a phase II trial of 20 patients with advanced peritoneal mesothelioma and progression or intolerance to prior platinum-pemetrexed chemotherapy [<a href="#rid97">97</a>]. The confirmed objective response rate (primary endpoint) was 40 percent (8 of 20 patients), and median response duration was 12.8 months. At one year, 61 percent remained progression-free. Responses were independent of PD-L1 overexpression, or presence of deficient mismatch repair. Grade 3 or worse toxicities included hypertension in eight (40 percent) patients, anemia in two, and thrombocytopenia, pancreatitis, ileus, abdominal pain, thromboembolic event, and transaminase elevation in one each.</p><p></p><p class="bulletIndent2">In our view, these data are too preliminary to support any specific recommendation for use of the combination in patients with peritoneal mesothelioma. Safety issues are a major concern. This group is potentially at risk for bowel perforation/anastomotic healing issues (which are seen at higher rates with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>) and the data set of 20 patients is too small to completely assess either safety or efficacy. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intestinal perforation/fistula formation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Predictive biomarkers</strong> – It's also not clear whether there is any role for archival tumor expression of PD-L1 to identify subsets of patients with peritoneal mesothelioma who might respond to agents targeting PD-1. The proportion of tissue microarray samples positive for PD-L1 expression (defined as &gt;1 percent tumor staining) using two FDA-approved immunohistochemistry markers was significantly higher in peritoneal (54 percent) than in pleural mesothelioma (18 to 22 percent) in one study, although only 13 peritoneal samples were evaluated [<a href="#rid98">98</a>]. Furthermore, others have demonstrated heterogeneity in PD-L1 expression that may be related to prior exposure to cytotoxic chemotherapy [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent2">A very small number (approximately 2 percent) of mesotheliomas have high levels of microsatellite instability (MSI-H; also referred to as deficient in mismatch repair [dMMR]) [<a href="#rid100">100</a>], which may predict benefit from inhibitors that target PD-1 or PD-L1. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'PD-1 and PD ligand 1/2'</a>.)</p><p></p><p class="bulletIndent2">In May 2017, the FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, a PD-1 inhibitor, for treatment of a variety of advanced solid tumors (including mesothelioma) that are MSI-H or dMMR, that progressed following prior treatment, and for which there are no satisfactory alternative treatment options. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p></p><p class="bulletIndent2">An important point is that MSI-H may indicate the presence of Lynch syndrome, an inherited condition that predisposes to several cancers, including possibly peritoneal mesothelioma [<a href="#rid101">101,102</a>]. In our view, all patients with peritoneal mesothelioma should be referred for germline testing given the high frequency of mutations in inherited cancer susceptibility genes in this disease (25 percent in one study [<a href="#rid103">103,104</a>]). (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Other factors'</a> and  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'</a>.)</p><p></p><p class="headingAnchor" id="H135336351"><span class="h1">PERITONEAL MESOTHELIOMA VARIANTS</span><span class="headingEndMark"> — </span>There are two rare variants of peritoneal mesothelioma. Both are characterized by indolent behavior and the potential for malignant transformation to MPM. Although controversial  (<a class="graphic graphic_algorithm graphicRef129848" href="/d/graphic/129848.html" rel="external">algorithm 1</a>), we suggest initial surgical resection alone rather than cytoreductive surgery (CRS) and hyperthermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) for patients with the indolent well-differentiated peritoneal mesothelioma and multicystic mesothelioma variants. Long-term follow-up is warranted.</p><p class="headingAnchor" id="H135336358"><span class="h2">Well-differentiated papillary mesothelioma</span><span class="headingEndMark"> — </span>Well-differentiated papillary mesothelioma is a rare clinicopathologic entity that is distinct from MPM. It occurs predominantly in women of reproductive age and most often arises from the peritoneal surfaces of the pelvis. It is typically identified as an incidental finding at surgery performed for another indication, and there is no reported association with asbestos exposure. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Well-differentiated papillary mesothelioma'</a>.)</p><p>Well-differentiated papillary mesothelioma is generally considered a low-grade malignancy, with a high rate of cure following complete surgical resection [<a href="#rid105">105,106</a>]. Long-term follow-up is required because of the potential to progress to true MPM [<a href="#rid106">106,107</a>]. Extensive CRS and HIPEC are not warranted initially because in most patients there is no clearcut evidence of progression with follow-up. In a series of 25 patients followed for a median of 47 months, 22 had no evidence of disease progression and no patient died of disease [<a href="#rid108">108</a>]. Only one recurrence was described, and this was incidentally found at the time of abdominal surgery for a colon cancer; three died of other causes.</p><p>A variant of well-differentiated papillary mesothelioma with invasive foci has been identified. Though rarely life threatening, it can be multifocal and is slightly more aggressive, with a greater propensity to recur [<a href="#rid109">109</a>].</p><p class="headingAnchor" id="H135336365"><span class="h2">Multicystic mesothelioma</span><span class="headingEndMark"> — </span>Multicystic mesothelioma (also termed benign cystic mesothelioma, peritoneal inclusion cyst) is an unusual cystic tumor that most commonly arises from the pelvic peritoneal surfaces in young and middle-aged women. Men represent only 17 percent of cases. The majority of cases present with chronic or intermittent lower abdominal or pelvic pain, but occasionally, the diagnosis is made incidentally at surgery or on cross-sectional imaging. There is no association with asbestos exposure. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Multicystic mesothelioma'</a>.)</p><p>Although the disease is well characterized histologically, the pathogenesis (in particular whether it represents a reactive mesothelial proliferation or a true neoplasm), natural history, and clinical management are not well defined. The clinical course is usually indolent, and surgical resection can be curative. However, long-term follow-up is needed, since local recurrence can occur in up to 50 percent from 1 to 27 years after initial diagnosis [<a href="#rid110">110,111</a>], and malignant transformation is reported, although rare.</p><p>Surgical cytoreduction and HIPEC has been associated with long-term progression-free survival [<a href="#rid112">112,113</a>] and may be best applied when there is evidence of progression after initial resection.</p><p>Proposed nonsurgical forms of therapy include observation for asymptomatic patients with an incidentally discovered lesion, hormonal therapy [<a href="#rid114">114,115</a>], image-guided sclerotherapy [<a href="#rid116">116</a>], and laser ablation [<a href="#rid117">117</a>]. However, experience with any of these is largely limited to single case reports with limited follow-up, and whether any of these alternative approaches provides long-term control or eliminates the risk of malignant transformation is not known. In addition, if definitive surgery is not pursued, a tissue sample is required for histologic diagnosis [<a href="#rid110">110,111</a>].</p><p class="headingAnchor" id="H3578067665"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/129231.html" rel="external">"Society guideline links: Peritoneal mesothelioma"</a>.)</p><p class="headingAnchor" id="H135336372"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that arises from the lining mesothelial cells of the peritoneum. As with mesothelioma arising in other sites, there is a strong relationship between asbestos exposure and the development of MPM, particularly in men. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The majority present with diffuse peritoneal involvement (diffuse MPM), and morbidity and mortality are almost entirely due to disease progression within the peritoneum and not distant metastatic spread. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Clinical presentation and imaging features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Candidates for cytoreductive surgery</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For selected otherwise healthy patients with diffuse MPM, no extraperitoneal disease spread, a good performance status, and who can be predicted to achieve complete surgical cytoreduction based on initial radiographic imaging we recommend regional therapy using cytoreductive surgery (CRS) and hyperthermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) rather than systemic or intraperitoneal chemotherapy or debulking surgery alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Cytoreductive surgery and intraperitoneal chemotherapy'</a> above.)</p><p></p><p class="bulletIndent3">Potential candidates for CRS/HIPEC should be referred to and treated in a center with expertise in the management of peritoneal surface malignancies. Additional factors including those derived intraoperatively, are used to select the optimal candidates for combined treatment. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The role of adjuvant or neoadjuvant systemic chemotherapy in conjunction with CRS plus HIPEC is uncertain, and there is no consensus as to the best approach. For patients in whom the timing of operative CRS and HIPEC must be delayed, we suggest a course of systemic chemotherapy until the definitive operation can be performed (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If upfront chemotherapy is chosen, we prefer a <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> plus platinum-containing regimen, similar to that used for nonresectable disease. (See <a class="local">'Contribution of systemic therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Following CRS/HIPEC, for those patients whose tumors display high-risk features (eg, the presence of deep tissue invasion, biphasic histology, baseline thrombocytosis), we suggest a course of systemic chemotherapy as consolidation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with optimal cytoreduction and no histopathologic features that would suggest increased risk of early recurrence, we would not pursue systemic therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Not candidates for cytoreductive surgery</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are not candidates for CRS/HIPEC, we suggest systemic chemotherapy rather than debulking surgery with or without chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3">For most patients, we suggest a pemetrexed-containing regimen over other chemotherapy options (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options include <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef67209" href="/d/graphic/67209.html" rel="external">table 6</a>) or pemetrexed plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>  (<a class="graphic graphic_table graphicRef81778" href="/d/graphic/81778.html" rel="external">table 7</a>) or <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> in addition to pemetrexed plus a platinum agent. (See <a class="local">'Pemetrexed-based regimens'</a> above.)</p><p></p><p class="bulletIndent3">When the chemotherapy regimen includes <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, concurrent supplementation with <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a> and <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> is needed to reduce toxicity.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The role of immunotherapy is evolving. In our view, the available data are insufficient to conclude that immunotherapy using a checkpoint inhibitor alone or in combination (ie, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) should be considered as a first-line treatment option for MPM. However, checkpoint inhibitor immunotherapy may be a reasonable option for second-line therapy and beyond. There are no consensus-based guidelines from the National Comprehensive Cancer Network or elsewhere that cover peritoneal mesothelioma. (See <a class="local">'Immunotherapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>All patients with peritoneal mesothelioma should be referred for germline testing given the high frequency of mutations in inherited cancer susceptibility genes in this disease; testing may reveal deficiency in mismatch repair (dMMR), which might predict benefit from <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>. (See <a class="local">'Immunotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of rare variants</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Although controversial  (<a class="graphic graphic_algorithm graphicRef129848" href="/d/graphic/129848.html" rel="external">algorithm 1</a>), for patients with the indolent well-differentiated peritoneal mesothelioma and multicystic mesothelioma variants we suggest initial surgical resection alone rather than CRS and HIPEC (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Long-term follow-up is warranted in these cases because of their indolent behavior. (See <a class="local">'Peritoneal mesothelioma variants'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kerrigan SA, Turnnir RT, Clement PB, et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 2002; 94:378.</a></li><li><a class="nounderline abstract_t">Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6.</a></li><li><a class="nounderline abstract_t">Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12:605.</a></li><li><a class="nounderline abstract_t">van der Bij S, Koffijberg H, Burgers JA, et al. Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 2012; 107:161.</a></li><li><a class="nounderline abstract_t">Antman KH, Pomfret EA, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983; 1:386.</a></li><li><a class="nounderline abstract_t">Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988; 93:159.</a></li><li><a class="nounderline abstract_t">Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997; 52:507.</a></li><li><a class="nounderline abstract_t">Kaya H, Sezgı C, Tanrıkulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma 2014; 61:433.</a></li><li><a class="nounderline abstract_t">de Boer NL, van Kooten JP, Damhuis RAM, et al. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study. Ann Surg Oncol 2019; 26:4222.</a></li><li><a class="nounderline abstract_t">Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. Ann Surg Oncol 2018; 25:2018.</a></li><li><a class="nounderline abstract_t">Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221:29.</a></li><li><a class="nounderline abstract_t">Passot G, Vaudoyer D, Villeneuve L, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. J Surg Oncol 2016; 113:796.</a></li><li><a class="nounderline abstract_t">Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988; 6:147.</a></li><li><a class="nounderline abstract_t">Sridhar KS, Doria R, Raub WA Jr, et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70:2969.</a></li><li><a class="nounderline abstract_t">Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118:547.</a></li><li><a class="nounderline abstract_t">Neumann V, Müller KM, Fischer M. [Peritoneal mesothelioma--incidence and etiology]. Pathologe 1999; 20:169.</a></li><li><a class="nounderline abstract_t">Bijelic L, Darcy K, Stodghill J, et al. Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database. Ann Surg Oncol 2020; 27:2974.</a></li><li><a class="nounderline abstract_t">Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015; 22:1686.</a></li><li><a class="nounderline abstract_t">Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014; 21:1159.</a></li><li><a class="nounderline abstract_t">Salo SAS, Ilonen I, Laaksonen S, et al. Malignant Peritoneal Mesothelioma: Treatment Options and Survival. Anticancer Res 2019; 39:839.</a></li><li><a class="nounderline abstract_t">Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007; 18:827.</a></li><li><a class="nounderline abstract_t">Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol 2007; 31:784.</a></li><li><a class="nounderline abstract_t">Foster JM, Sleightholm R, Patel A, et al. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures. JAMA Netw Open 2019; 2:e186847.</a></li><li><a class="nounderline abstract_t">Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008; 98:268.</a></li><li><a class="nounderline abstract_t">Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 2007; 14:2270.</a></li><li><a class="nounderline abstract_t">Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008; 15:754.</a></li><li><a class="nounderline abstract_t">Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560.</a></li><li><a class="nounderline abstract_t">Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89:269.</a></li><li><a class="nounderline abstract_t">Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 2008; 31:49.</a></li><li><a class="nounderline abstract_t">Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007; 14:41.</a></li><li><a class="nounderline abstract_t">Yan TD, Popa E, Brun EA, et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 2006; 93:1536.</a></li><li><a class="nounderline abstract_t">Lee M, Alexander HR, Burke A. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy. Pathology 2013; 45:464.</a></li><li><a class="nounderline abstract_t">Li YC, Khashab T, Terhune J, et al. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 2017; 24:2259.</a></li><li><a class="nounderline abstract_t">Jin S, Cao S, Cao J, et al. Predictive factors analysis for malignant peritoneal mesothelioma. J Gastrointest Surg 2015; 19:319.</a></li><li><a class="nounderline abstract_t">Cao C, Yan TD, Deraco M, et al. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012; 23:1494.</a></li><li><a class="nounderline abstract_t">Yan TD, Haveric N, Carmignani CP, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005; 103:839.</a></li><li><a class="nounderline abstract_t">Chandramohan A, Thrower A, Shah N, Mohamed F. Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol 2017; 90:20170361.</a></li><li><a class="nounderline abstract_t">Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options. Oncology (Williston Park) 2004; 18:51.</a></li><li><a class="nounderline abstract_t">Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. Oncology (Williston Park) 2004; 18:207.</a></li><li><a class="nounderline abstract_t">Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003; 12:649.</a></li><li><a class="nounderline abstract_t">Aydin N, Sardi A, Milovanov V, et al. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center. Am Surg 2015; 81:1253.</a></li><li><a class="nounderline abstract_t">Marmor RA, Kelly KJ, Lowy AM, Baumgartner JM. Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery. Ann Surg Oncol 2016; 23:1461.</a></li><li><a class="nounderline abstract_t">Greenbaum A, Alexander HR. Peritoneal mesothelioma. Transl Lung Cancer Res 2020; 9:S120.</a></li><li><a class="nounderline abstract_t">Blackham AU, Shen P, Stewart JH, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 2010; 17:2720.</a></li><li><a class="nounderline abstract_t">Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013; 153:779.</a></li><li><a class="nounderline abstract_t">Hubert J, Thiboutot E, Dubé P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis. Surg Oncol 2015; 24:41.</a></li><li><a class="nounderline abstract_t">Malgras B, Gayat E, Aoun O, et al. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. Ann Surg Oncol 2018; 25:3271.</a></li><li><a class="nounderline abstract_t">Yan TD, Edwards G, Alderman R, et al. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases. Ann Surg Oncol 2007; 14:515.</a></li><li><a class="nounderline abstract_t">Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 2009; 99:109.</a></li><li><a class="nounderline abstract_t">Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006; 13:405.</a></li><li><a class="nounderline abstract_t">Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67:999.</a></li><li><a class="nounderline abstract_t">Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:686.</a></li><li><a class="nounderline abstract_t">Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27:6237.</a></li><li><a class="nounderline abstract_t">Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359.</a></li><li><a class="nounderline abstract_t">Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol 2013; 20:555.</a></li><li><a class="nounderline abstract_t">Hommell-Fontaine J, Isaac S, Passot G, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol 2013; 20:3892.</a></li><li><a class="nounderline abstract_t">Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013; 49:3140.</a></li><li><a class="nounderline abstract_t">Shetty SJ, Bathla L, Govindarajan V, et al. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg 2014; 80:348.</a></li><li><a class="nounderline abstract_t">Hassan R, Alexander R, Antman K, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006; 17:1615.</a></li><li><a class="nounderline abstract_t">Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol 2014; 21:3947.</a></li><li><a class="nounderline abstract_t">Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 2014; 21:1474.</a></li><li><a class="nounderline abstract_t">Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998; 83:1251.</a></li><li><a class="nounderline abstract_t">Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol 2015; 22:1680.</a></li><li><a class="nounderline abstract_t">Wong J, Koch AL, Deneve JL, et al. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol 2014; 21:1480.</a></li><li><a class="nounderline abstract_t">Huang Y, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2015; 41:1373.</a></li><li><a class="nounderline abstract_t">Llanos MD, Sugarbaker PH. Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. Eur J Surg Oncol 2017; 43:138.</a></li><li><a class="nounderline abstract_t">Hamilton TD, Taylor EL, Cannell AJ, et al. Impact of Major Complications on Patients' Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 2016; 23:2946.</a></li><li><a class="nounderline abstract_t">Ali YM, Sweeney J, Shen P, et al. Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. Ann Surg Oncol 2020; 27:117.</a></li><li><a class="nounderline abstract_t">Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. Ann Surg Oncol 2020; 27:1774.</a></li><li><a class="nounderline abstract_t">Naffouje SA, Tulla KA, Salti GI. The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. Med Oncol 2018; 35:69.</a></li><li><a class="nounderline abstract_t">Deraco M, Baratti D, Hutanu I, et al. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2013; 20:1093.</a></li><li><a class="nounderline abstract_t">Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer 2016; 65:69.</a></li><li><a class="nounderline abstract_t">Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:676.</a></li><li><a class="nounderline abstract_t">Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38:111.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.</a></li><li><a class="nounderline abstract_t">van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881.</a></li><li><a class="nounderline abstract_t">Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 2011; 32:102.</a></li><li><a class="nounderline abstract_t">Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005; 7:40.</a></li><li><a class="nounderline abstract_t">Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009; 64:211.</a></li><li><a class="nounderline abstract_t">Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387:1405.</a></li><li><a class="nounderline abstract_t">Simon GR, Verschraegen CF, Jänne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008; 26:3567.</a></li><li><a class="nounderline abstract_t">Le DT, Deavers M, Hunt K, et al. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest 2003; 21:682.</a></li><li><a class="nounderline abstract_t">Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912.</a></li><li><a class="nounderline abstract_t">Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63:94.</a></li><li><a class="nounderline abstract_t">Varghese S, Chen Z, Bartlett DL, et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 2011; 117:361.</a></li><li><a class="nounderline abstract_t">Hung YP, Dong F, Watkins JC, et al. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. JAMA Oncol 2018; 4:235.</a></li><li><a class="nounderline abstract_t">Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol 2017; 35S: ASCO #LBA8507.</a></li><li><a class="nounderline abstract_t">Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021; 22:1530.</a></li><li><a class="nounderline abstract_t">Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397:375.</a></li><li class="breakAll">Nivolumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s089lbl.pdf (Accessed on October 05, 2020).</li><li class="breakAll">Ipilimumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s115lbl.pdf (Accessed on October 05, 2020).</li><li><a class="nounderline abstract_t">Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 2017; 18:1261.</a></li><li><a class="nounderline abstract_t">Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019; 5:351.</a></li><li class="breakAll">Desai A, Karrison T, Rose B, et al. Phase II Trial of Pembrolizumab (NCT02399371) In
Previously-Treated Malignant Mesothelioma (MM): Final Analysis (abstract OA08.03). J Thorac Oncol 2018; 13:S339. Abstract available online at https://www.jto.org/article/S1556-0864(18)31235-8/pdf (Accessed on May 21, 2019).</li><li><a class="nounderline abstract_t">Desai A, Karrison T, Rose B, et al. OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis. J Thorac Oncol 2018; 13:S339.</a></li><li><a class="nounderline abstract_t">Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med 2018; 6:451.</a></li><li><a class="nounderline abstract_t">Raghav K, Liu S, Overman MJ, et al. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 2021; 11:2738.</a></li><li><a class="nounderline abstract_t">Chapel DB, Stewart R, Furtado LV, et al. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum Pathol 2019; 87:11.</a></li><li><a class="nounderline abstract_t">White MG, Schulte JJ, Xue L, et al. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer 2021; 124:564.</a></li><li><a class="nounderline abstract_t">Bonneville R, Krook MA, Kautto EA, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol 2017; 2017.</a></li><li><a class="nounderline abstract_t">Karamurzin Y, Zeng Z, Stadler ZK, et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol 2012; 43:1677.</a></li><li><a class="nounderline abstract_t">Lu Y, Milchgrub S, Khatri G, Gopal P. Metachronous Uterine Endometrioid Adenocarcinoma and Peritoneal Mesothelioma in Lynch Syndrome: A Case Report. Int J Surg Pathol 2017; 25:253.</a></li><li><a class="nounderline abstract_t">Panou V, Gadiraju M, Wolin A, et al. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol 2018; 36:2863.</a></li><li><a class="nounderline abstract_t">Hassan R, Morrow B, Thomas A, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A 2019; 116:9008.</a></li><li><a class="nounderline abstract_t">Hoekstra AV, Riben MW, Frumovitz M, et al. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005; 98:161.</a></li><li><a class="nounderline abstract_t">Bürrig KF, Pfitzer P, Hort W. Well-differentiated papillary mesothelioma of the peritoneum: a borderline mesothelioma. Report of two cases and review of literature. Virchows Arch A Pathol Anat Histopathol 1990; 417:443.</a></li><li><a class="nounderline abstract_t">Hejmadi R, Ganesan R, Kamal NG. Malignant transformation of a well-differentiated peritoneal papillary mesothelioma. Acta Cytol 2003; 47:517.</a></li><li><a class="nounderline abstract_t">Malpica A, Sant'Ambrogio S, Deavers MT, Silva EG. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol 2012; 36:117.</a></li><li><a class="nounderline abstract_t">Churg A, Allen T, Borczuk AC, et al. Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol 2014; 38:990.</a></li><li><a class="nounderline abstract_t">Vallerie AM, Lerner JP, Wright JD, Baxi LV. Peritoneal inclusion cysts: a review. Obstet Gynecol Surv 2009; 64:321.</a></li><li><a class="nounderline abstract_t">Søreide JA, Søreide K, Körner H, et al. Benign peritoneal cystic mesothelioma. World J Surg 2006; 30:560.</a></li><li><a class="nounderline abstract_t">Baratti D, Kusamura S, Nonaka D, et al. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol 2007; 14:2790.</a></li><li><a class="nounderline abstract_t">Chua TC, Yan TD, Deraco M, et al. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg 2011; 98:60.</a></li><li><a class="nounderline abstract_t">Letterie GS, Yon JL. The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma. Gynecol Oncol 1998; 70:131.</a></li><li><a class="nounderline abstract_t">Letterie GS, Yon JL. Use of a long-acting GnRH agonist for benign cystic mesothelioma. Obstet Gynecol 1995; 85:901.</a></li><li><a class="nounderline abstract_t">Jeong JY, Kim SH. Sclerotherapy of peritoneal inclusion cysts: preliminary results in seven patients. Korean J Radiol 2001; 2:164.</a></li><li><a class="nounderline abstract_t">Iacoponi S, Calleja J, Hernandez G, de la Cuesta RS. Asymptomatic peritoneal carcinomatosis originating from benign cystic peritoneal mesothelioma. Ecancermedicalscience 2015; 9:605.</a></li></ol></div><div id="topicVersionRevision">Topic 82913 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11905410" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989414" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567020" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A review of peritoneal mesothelioma at the Washington Cancer Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22644294" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognosis and prognostic factors of patients with mesothelioma: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6668506" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Peritoneal mesothelioma: natural history and response to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335148" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227715" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24645844" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31620941" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29721724" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7826158" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Peritonectomy procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27110915" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335886" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1451080" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : New strategies are needed in diffuse malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1624547" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10412176" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [Peritoneal mesothelioma--incidence and etiology].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32006127" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25124472" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24322529" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711965" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Malignant Peritoneal Mesothelioma: Treatment Options and Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130182" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166853" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646202" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18726890" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Consensus statement on peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464543" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18080166" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673042" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12908781" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical presentation of peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376228" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039392" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17048277" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sex difference in diffuse malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846294" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324285" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25297446" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Predictive factors analysis for malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056853" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Importance of gender in diffuse malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637690" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28830230" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14768406" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008058" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567023" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26736164" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542584" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32206577" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20422458" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23489943" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25680983" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29978366" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17031722" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016259" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16485159" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603562" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prospective trial for the treatment of malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621431" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comprehensive management of diffuse malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917862" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8849962" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23233234" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A novel nomogram for peritoneal mesothelioma predicts survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23800898" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23831335" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24887664" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16600983" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24841356" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Current trends in the management of malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23982251" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740093" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25120250" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24158467" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26227745" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27612411" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27094685" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Impact of Major Complications on Patients' Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31069554" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32285273" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29651664" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23456386" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27472649" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616827" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Systemic chemotherapy in the management of malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399121" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860938" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192580" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21500129" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Update on malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098243" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19042053" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26719230" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18640937" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14628425" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099320" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phase II study of vinorelbine in patients with malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486273" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20839315" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28910456" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34656227" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33485464" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33485464" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33485464" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28729154" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30605211" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30605211" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773326" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34261675" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30794891" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33100328" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850653" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Landscape of Microsatellite Instability Across 39 Cancer Types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516243" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27903930" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Metachronous Uterine Endometrioid Adenocarcinoma and Peritoneal Mesothelioma in Lynch Syndrome: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113886" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30975761" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894368" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2122588" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Well-differentiated papillary mesothelioma of the peritoneum: a borderline mesothelioma. Report of two cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789944" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Malignant transformation of a well-differentiated peritoneal papillary mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22024662" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24618613" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Well-differentiated papillary mesothelioma with invasive foci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19386139" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Peritoneal inclusion cysts: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547615" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Benign peritoneal cystic mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17661150" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20872843" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9698490" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7724156" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Use of a long-acting GnRH agonist for benign cystic mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11752988" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Sclerotherapy of peritoneal inclusion cysts: preliminary results in seven patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26715942" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Asymptomatic peritoneal carcinomatosis originating from benign cystic peritoneal mesothelioma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
